

## Special Issue

# Exploring Conventional and Alternative Animal Models in Biomedical Research (Biomedicines)

### Message from the Guest Editors

This Special Issue is a joint effort to bring together expertise and insights from Pharmaceutics and Biomedicines journals, providing a platform to explore the latest advancements in biomedical research models. For authors interested in contributing, Pharmaceutics welcomes manuscripts focused on drug delivery, absorption, distribution, metabolism, excretion (ADME), pharmacokinetics, pharmacodynamics, pharmacometrics, and other technologies that optimize therapeutic outcomes. Studies exploring how traditional and alternative preclinical models advance these areas, improve drug efficacy, and enhance clinical translation are particularly encouraged. Meanwhile, Biomedicines encourages submissions that utilize traditional and alternative animal models, only those focusing on human diseases, as well as studies examining the biological and mechanistic aspects of treatments. By incorporating diverse perspectives and cutting-edge research, the issue seeks to deepen our understanding of how these studies can complement each other in addressing complex biological questions, improving disease treatment accuracy, and enhancing the translation of research findings into clinical applications.

### Guest Editors

Dr. Elisa Panzarini

Department of Biological and Environmental Sciences and Technologies, University of Salento, 73100 Lecce, Italy

Dr. Stefania Mariano

Department of Mathematics and Physics, University of Salento, 73100 Lecce, Italy

### Deadline for manuscript submissions

31 August 2025



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/230329](https://mdpi.com/si/230329)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).